News
FDA Approves OraVerse
Significant event! First time FDA approved dental anesthetic reversal agent OraVerse produced by Novalar Pharmaceuticals, Inc. Receives Approval.
Novalar Pharmaceuticals, Inc. is pharmaceutical company, specializing on dental care. Today is was announced FDA has given marketing approval for OraVerse (phentolamine mesylate). Novalar begins to sell OraVerse, an agent for the reversal of soft-tissue anesthesia and the associated functional deficits resulting from a local dental anesthetic, in late 2008.
OraVerse also called phentolamine mesylate is an injection. For the moment it is the only one existing local anesthetic reversal agent. It acts so that the normal sensation and function following restorative and periodontal maintenance procedures returns faster than from any known anesthetic.
OraVerse is a medicine used for the reversal of soft-tissue anesthesia. This is a kind of anesthesia of the lip and tongue is gained by submucosal injection of a local anesthetic that contains a vasoconstrictor. However, OraVerse is not recommended by FDA for use in children who are younger than six years old because safety and effectiveness is unknown. This will be estimated by later research on this issue.
